Nature Communications (Dec 2020)
Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy
- Amy J. Wisdom,
- Yvonne M. Mowery,
- Cierra S. Hong,
- Jonathon E. Himes,
- Barzin Y. Nabet,
- Xiaodi Qin,
- Dadong Zhang,
- Lan Chen,
- Hélène Fradin,
- Rutulkumar Patel,
- Alex M. Bassil,
- Eric S. Muise,
- Daniel A. King,
- Eric S. Xu,
- David J. Carpenter,
- Collin L. Kent,
- Kimberly S. Smythe,
- Nerissa T. Williams,
- Lixia Luo,
- Yan Ma,
- Ash A. Alizadeh,
- Kouros Owzar,
- Maximilian Diehn,
- Todd Bradley,
- David G. Kirsch
Affiliations
- Amy J. Wisdom
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Yvonne M. Mowery
- Department of Radiation Oncology, Duke University Medical Center
- Cierra S. Hong
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Jonathon E. Himes
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Barzin Y. Nabet
- Stanford Cancer Institute, Stanford University
- Xiaodi Qin
- Duke Cancer Institute
- Dadong Zhang
- Duke Cancer Institute
- Lan Chen
- Merck & Co., Inc
- Hélène Fradin
- Duke Center for Genomic and Computational Biology
- Rutulkumar Patel
- Department of Radiation Oncology, Duke University Medical Center
- Alex M. Bassil
- Department of Radiation Oncology, Duke University Medical Center
- Eric S. Muise
- Merck & Co., Inc
- Daniel A. King
- Stanford Cancer Institute, Stanford University
- Eric S. Xu
- Department of Radiation Oncology, Duke University Medical Center
- David J. Carpenter
- Department of Radiation Oncology, Duke University Medical Center
- Collin L. Kent
- Department of Radiation Oncology, Duke University Medical Center
- Kimberly S. Smythe
- Fred Hutchinson Cancer Research Center
- Nerissa T. Williams
- Department of Radiation Oncology, Duke University Medical Center
- Lixia Luo
- Department of Radiation Oncology, Duke University Medical Center
- Yan Ma
- Department of Radiation Oncology, Duke University Medical Center
- Ash A. Alizadeh
- Stanford Cancer Institute, Stanford University
- Kouros Owzar
- Duke Cancer Institute
- Maximilian Diehn
- Stanford Cancer Institute, Stanford University
- Todd Bradley
- Department of Medicine, Duke University Medical Center
- David G. Kirsch
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- DOI
- https://doi.org/10.1038/s41467-020-19917-0
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
Promising results of cancer therapies in transplant tumor models often fail to predict efficacy in clinical trials. Here the authors show that, while transplant tumors are cured by radiotherapy and PD-1 blockade, autochthonous sarcomas are resistant to the identical treatment, recapitulating the immune landscape and resistance to checkpoint blockade observed in most sarcoma patients.
